Editorial: Predictive Factors and Survival Outcome of Conversion Therapy for Unresectable Hepatocellular Carcinoma Patients Receiving Atezolizumab and Bevacizumab: Comparative Analysis of Conversion, Partial Response and Complete Response Patients. Authors' Reply

被引：0
|
作者：
Hatanaka, Takeshi [1 ]
Kakizaki, Satoru [2 ,3 ]
Hiraoka, Atsushi [4 ]
Tada, Toshifumi [5 ,6 ]
Kumada, Takashi [7 ]
机构：
[1] Gunma Saiseikai Maebashi Hosp, Dept Gastroenterol, Maebashi, Japan
[2] NHO Takasaki Gen Med Ctr, Dept Clin Res, Takasaki, Japan
[3] Gunma Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Maebashi, Japan
[4] Ehime Prefectural Cent Hosp, Gastroenterol Ctr, Matsuyama, Japan
[5] Japanese Red Cross Himeji Hosp, Dept Internal Med, Himeji, Japan
[6] Kobe Univ, Grad Sch Med, Dept Internal Med, Div Gastroenterol, Kobe, Japan
[7] Gifu Kyoritsu Univ, Ogaki, Japan
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2024年 / 60卷 / 10期
关键词：
D O I：
10.1111/apt.18319
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1469 / 1470
页数：2
相关论文
共 21 条
  • [1] Editorial: Predictive Factors and Survival Outcome of Conversion Therapy for Unresectable Hepatocellular Carcinoma Patients Receiving Atezolizumab and Bevacizumab: Comparative Analysis of Conversion, Partial Response and Complete Response Patients
    Gorgulho, Joao
    von Felden, Johann
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (10) : 1467 - 1468
  • [2] Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Hiraoka, Atsushi
    Tada, Toshifumi
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishikawa, Hiroki
    Nishimura, Takashi
    Kawata, Kazuhito
    Kosaka, Hisashi
    Naganuma, Atsushi
    Yata, Yutaka
    Ohama, Hideko
    Kuroda, Hidekatsu
    Matono, Tomomitsu
    Aoki, Tomoko
    Kanayama, Yuki
    Tanaka, Kazunari
    Tada, Fujimasa
    Nouso, Kazuhiro
    Morishita, Asahiro
    Tsutsui, Akemi
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Imai, Michitaka
    Nakamura, Shinichiro
    Enomoto, Hirayuki
    Kaibori, Masaki
    Hiasa, Yoichi
    Kudo, Masatoshi
    Kumada, Takashi
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (10) : 1361 - 1373
  • [3] The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in Japan
    Shimose, Shigeo
    Saeki, Issei
    Ito, Takanori
    Takeuchi, Yasuto
    Tani, Joji
    Tomonari, Tetsu
    Sasaki, Ryu
    Sasaki, Kyo
    Kakizaki, Satoru
    Hatanaka, Takeshi
    Iwamoto, Hideki
    Tanabe, Norikazu
    Yamamoto, Takafumi
    Naganuma, Atsushi
    Shirono, Tomotake
    Kanayama, Yuki
    Nishina, Sohji
    Takayama, Tetsuji
    Kobara, Hideki
    Otsuka, Motoyuki
    Kawashima, Hiroki
    Takami, Taro
    Kawaguchi, Takumi
    Hepatology InVestigator Experts Japan HIVE-J Study Grp
    HEPATOLOGY INTERNATIONAL, 2025,
  • [4] Prognostic Value of Clinical Complete Response for Patients with Initially Unresectable Hepatocellular Carcinoma after Conversion with Triple Therapy
    Wu, Jun-Yi
    Zeng, Zhen-Xin
    Li, Yi-Nan
    Zhang, Zhi-Bo
    Zhuang, Shao-Wu
    Li, Bin
    Zhou, Jian-Yin
    Li, Shu-Qun
    Liu, De-Yi
    Li, Han
    Ou, Xiang-Ye
    Wu, Jia-Yi
    Yan, Mao-Lin
    LIVER CANCER, 2025,
  • [5] Conversion to Curative Resection and Pathological Complete Response Following Targeted Therapies With Atezolizumab and Bevacizumab for Initially Unresectable Hepatocellular Carcinoma: A Case Report
    Matsuoka, Taisuke
    Fujikawa, Takahisa
    Uemoto, Yusuke
    Aibe, Yuki
    Hasegawa, Suguru
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
  • [6] Study of predictive factors of complete response after chemoembolization for unresectable hepatocellular carcinoma in 162 patients
    Younes, El Hassani
    Zahra, Hamdoun Fatima
    Soumaya, Ben Maamar
    Maria, Lahlali
    Nada, Lahmidani
    Hakima, Abid
    Samira, El Fakir
    Meriem, Haloua
    Badreddine, Alami
    Youssef, Hafidi
    Imane, Kamaoui
    Meryem, Boubbou
    Noureddine, Aqodad
    Adil, Ibrahimi Sidi
    Mustapha, Maaroufi
    Youssef, Alaoui Lamrani Moulay
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2020, 6 (04) : 313 - 320
  • [7] Pathological complete response of hepatocellular carcinoma confirmed by conversion hepatectomy following atezolizumab plus bevacizumab therapy: a case report and literature review
    Sato, Shun
    Aoki, Taku
    Matsumoto, Takatsugu
    Shiraki, Takayuki
    Mori, Shozo
    Iso, Yukihiro
    Nemoto, Takehiko
    Onishi, Toshihiko
    Iijima, Makoto
    Ishida, Kazuyuki
    CLINICAL JOURNAL OF GASTROENTEROLOGY, 2024, 17 (02) : 292 - 299
  • [8] Pathological complete response of hepatocellular carcinoma confirmed by conversion hepatectomy following atezolizumab plus bevacizumab therapy: a case report and literature review
    Shun Sato
    Taku Aoki
    Takatsugu Matsumoto
    Takayuki Shiraki
    Shozo Mori
    Yukihiro Iso
    Takehiko Nemoto
    Toshihiko Onishi
    Makoto Iijima
    Kazuyuki Ishida
    Clinical Journal of Gastroenterology, 2024, 17 : 292 - 299
  • [9] Characteristics and Prognosis of Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab Combination Therapy Who Achieved Complete Response
    Kuzuya, Teiji
    Kawabe, Naoto
    Muto, Hisanori
    Tachi, Yoshihiko
    Ukai, Takeshi
    Wada, Yuryo
    Komura, Gakushi
    Nakano, Takuji
    Tanaka, Hiroyuki
    Nakaoka, Kazunori
    Ohno, Eizaburo
    Funasaka, Kohei
    Nagasaka, Mitsuo
    Miyahara, Ryoji
    Hirooka, Yoshiki
    CURRENT ONCOLOGY, 2024, 31 (10) : 6218 - 6231
  • [10] External beam radiation therapy improves the response to Atezolizumab plus Bevacizumab in patients with unresectable hepatocellular carcinoma with portal vein tumor thrombosis
    Lee, Yunjeong
    Kim, Jin-Wook
    JOURNAL OF HEPATOLOGY, 2024, 80 : S450 - S450
123